Delving into the Latest Updates on Ichor Biologics LLC with Synapse

概览

关联

2

项与 Ichor Biologics LLC 相关的药物

JL-16

靶点

安第斯汉坦病毒糖蛋白

作用机制

安第斯汉坦病毒糖蛋白抑制剂

在研机构-

原研机构

Ichor Biologics LLC

[+1]

在研适应症-

非在研适应症

汉坦病毒感染

最高研发阶段无进展

首次获批国家/地区-

首次获批日期-

MIB-22

靶点

安第斯汉坦病毒糖蛋白

作用机制

安第斯汉坦病毒糖蛋白抑制剂

在研机构-

原研机构

Ichor Biologics LLC

[+1]

在研适应症-

非在研适应症

汉坦病毒感染

最高研发阶段无进展

首次获批国家/地区-

首次获批日期-

100 项与 Ichor Biologics LLC 相关的临床结果

登录后查看更多信息

0 项与 Ichor Biologics LLC 相关的专利（医药）

登录后查看更多信息

9

项与 Ichor Biologics LLC 相关的文献（医药）

2025-04-25·Cancer Research

Abstract LB001: Discovery of a monoclonal antibody that binds CD16a to inhibit the shedding and promote anti-tumor immunity

作者: Hernandez, Matthew ; Chen, Benjamin K. ; Taciane da Silva Bortoleti, Bruna ; Brandão, Luiza Ribeiro de Lima ; de Andrade, Lucas Ferrari ; Alvarez, Raymond ; Zhong, Xiaoxuan ; Fraidenburg, Melanie ; Marron, Thomas ; Pimenta, Ruan ; Silva, Pedro Henrique Alves da ; Maurer, Stefanie ; Quasem, Sophia

AbstractCD16a is the Fc receptor that triggers antibody-dependent cellular cytotoxicity (ADCC) by natural killer (NK) cells. Several antibody therapies bind CD16a to induce anti-tumor immune responses. However, CD16a undergoes cleavage-mediated downregulation by ADAM17, a protease with broad specificity to over one-hundred different types of proteins. “CD16a shedding” is a therapeutic target because it decreases the number of CD16a molecules available for antibody engagement. To overcome the ADAM17’s broad specificity, we developed a monoclonal antibody (F9H4) that binds CD16a to inhibit the cleavage. F9H4 is extremely effective in inhibiting the shedding and retaining CD16a on the NK cell surface. When combined with cetuximab for CD16a engagement, F9H4 increased ADCC against human lung cancer cell lines. F9H4+cetuximab inhibited the development of tumors in the lungs of immunodeficient mice that were inoculated with human lung cancer cell line and NK cells. Notably, a major advantage of F9H4 is that it inhibits the shedding in a CD16a specific manner and thereby it enabled physiologically relevant studies in immunocompetent hosts. Consistent with that notion, we applied F9H4 to Fc gamma receptor-humanized (hFcR) mice, which are immunocompetent. F9H4+cetuximab inhibited tumor growth in hFcR mice, and such effect was NK cell mediated. Cetuximab induced the CD16a shedding by blood NK cells in vivo, but F9H4 inhibited it. To generate insights about the clinical significance of CD16a shedding, we applied the tissue explant technology to tumor samples from patients. Through that, we discovered that cetuximab induced whereas F9H4 inhibited the CD16a shedding by primary tumor-infiltrating leukocytes from untreated patients with early-stage non-small cell lung cancer. Finally, we developed an Fc-enhanced version of cetuximab, by point mutations in the Fc region, and discovered that it synergized with F9H4 to promote ADCC. Therefore, F9H4 represents a new means to promote NK cell-driven immunity and applicable to cancer immunotherapy pre-clinical research.Citation Format:Bruna Taciane da Silva Bortoleti, Sophia Quasem, Stefanie Maurer, Xiaoxuan Zhong, Ruan Pimenta, Luiza Ribeiro de Lima Brandão, Matthew Hernandez, Melanie Fraidenburg, Pedro Henrique Alves da Silva, Raymond Alvarez, Benjamin K. Chen, Thomas Marron, Lucas Ferrari de Andrade. Discovery of a monoclonal antibody that binds CD16a to inhibit the shedding and promote anti-tumor immunity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr LB001.

2022-05-01·Cell Reports

IgG targeting distinct seasonal coronavirus- conserved SARS-CoV-2 spike subdomains correlates with differential COVID-19 disease outcomes

Article

作者: Alvarez, Raymond A ; Bravo, Felipe ; Bowman, James W ; Garrido, Jose L ; Pinos, Yazmin ; Bahl, Christopher D ; Calvo, Mario ; Brachman, Rebecca A ; McGee, Sarah ; Medina, Matías A ; Barria, Maria Ines ; Fuentes-Villalobos, Francisco

Despite SARS-CoV-2 being a "novel" virus, early detection of anti-spike IgG in severe COVID-19 patients may be caused by the amplification of humoral memory responses against seasonal coronaviruses. Here, we examine this phenomenon by characterizing anti-spike IgG responses in non-hospitalized convalescent individuals across a spectrum of COVID-19 severity. We observe that disease severity positively correlates with anti-spike IgG levels, IgG cross-reactivity against other betacoronaviruses (β-CoVs), and FcγR activation. Analysis of IgG targeting β-CoV-conserved and non-conserved immunodominant epitopes within the SARS-CoV-2 spike protein revealed epitope-specific relationships: IgG targeting the conserved heptad repeat (HR) 2 region significantly correlates with milder disease, while targeting the conserved S2'FP region correlates with more severe disease. Furthermore, a lower HR2-to-S2'FP IgG-binding ratio correlates with greater disease severity, with ICU-hospitalized COVID-19 patients showing the lowest HR2/S2'FP ratios. These findings suggest that HR2/S2'FP IgG profiles may predict disease severity and offer insight into protective versus deleterious humoral recall responses.

2018-11-21·Science Translational Medicine1区 · 医学

Two recombinant human monoclonal antibodies that protect against lethal Andes hantavirus infection in vivo

1区 · 医学

Article

作者: Rioseco, Maria L. ; Barria, Maria I. ; Riquelme, Raul ; Prescott, Joseph ; Alvarez, Raymond ; Garrido, Jose L. ; Bravo, Felipe ; Feldmann, Heinz ; Haddock, Elaine ; Williamson, Brandi N. ; Calvo, Mario ; Salas, Alexis

Post-exposure highly potent human monoclonal antibodies target Andes hantavirus glycoprotein in a hamster hantavirus cardiopulmonary syndrome model.

1

项与 Ichor Biologics LLC 相关的新闻（医药）

2019-05-13

·BioPortfolio

Ichor Biologics is awarded $300K by the NIH to develop therapeutic antibodies to treat deadly hantavirus infections.

This article has expired, however you can still download the PDF. Preview: Ichor Biologics received a $300,000 grant from the National Institutes of Health to utilize its platform technology to develop broadly neutralizing antibodies against deadly hantavirus infections. Hantavirus infections ...

抗体

100 项与 Ichor Biologics LLC 相关的药物交易

登录后查看更多信息

100 项与 Ichor Biologics LLC 相关的转化医学

登录后查看更多信息